Literature DB >> 29971815

Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence.

Valeria Avataneo1,2, Amedeo De Nicolò1,2, Franco Rabbia3,4, Elisa Perlo3,4, Jacopo Burrello3,4, Elena Berra3,4, Marco Pappaccogli3,4, Jessica Cusato1,2, Antonio D'Avolio1,2, Giovanni Di Perri1,2, Franco Veglio3,4.   

Abstract

AIMS: Arterial hypertension is an important cardiovascular risk factor. A substantial proportion of patients show resistance to antihypertensive treatment but poor adherence to medication regimens is also a significant cause of treatment failure. In this context, therapeutic drug monitoring (TDM) could be useful. The objective of this study was to assess adherence to treatment in patients with resistant hypertension by TDM and to identify parameters that predict nonadherence.
METHODS: Liquid chromatography tandem mass spectrometry was used to quantify a wide panel of antihypertensive drugs in human plasma to assess treatment compliance. Associations between TDM-determined adherence profiles, self-reported adherence and other patient-related clinical, anthropometric or demographic features were evaluated as potentially useful pre-TDM predictors of poor adherence.
RESULTS: TDM was performed on 50 patients with suspected resistant hypertension: 24% of patients partially complied to treatment and 18% were nonadherent. No concordance was observed with questionnaire results, while nonadherence was associated with high diastolic blood pressure, high heart rate, previous onset of stroke and previous use of invasive treatments, including renal denervation or baroreceptor stimulation.
CONCLUSIONS: This evidence highlights the high prevalence of poor adherence in patients with resistant hypertension and the need for caution in using invasive approaches. These preliminary data require validation in a larger cohort, to confirm the need for TDM in routine clinical practice.
© 2018 The British Pharmacological Society.

Entities:  

Keywords:  adherence; clinical pharmacology; hypertension; mass spectrometry; therapeutic drug monitoring

Mesh:

Substances:

Year:  2018        PMID: 29971815      PMCID: PMC6177709          DOI: 10.1111/bcp.13706

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  36 in total

Review 1.  Resistant hypertension.

Authors:  Robert H Fagard
Journal:  Heart       Date:  2012-02       Impact factor: 5.994

Review 2.  A meta-analysis of the association between adherence to drug therapy and mortality.

Authors:  Scot H Simpson; Dean T Eurich; Sumit R Majumdar; Rajdeep S Padwal; Ross T Tsuyuki; Janice Varney; Jeffrey A Johnson
Journal:  BMJ       Date:  2006-06-21

3.  Resistant hypertension: incidence, prevalence, and prognosis.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

4.  Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension.

Authors:  Stephanie Brinker; Ambarish Pandey; Colby Ayers; Angela Price; Prafull Raheja; Debbie Arbique; Sandeep R Das; Ethan A Halm; Norman M Kaplan; Wanpen Vongpatanasin
Journal:  J Am Coll Cardiol       Date:  2013-12-04       Impact factor: 24.094

5.  Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence.

Authors:  Valeria Avataneo; Amedeo De Nicolò; Franco Rabbia; Elisa Perlo; Jacopo Burrello; Elena Berra; Marco Pappaccogli; Jessica Cusato; Antonio D'Avolio; Giovanni Di Perri; Franco Veglio
Journal:  Br J Clin Pharmacol       Date:  2018-08-15       Impact factor: 4.335

Review 6.  Can drugs work in patients who do not take them? The problem of non-adherence in resistant hypertension.

Authors:  Marcel Ruzicka; Swapnil Hiremath
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

Review 7.  Renal denervation and hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka; Murray D Esler
Journal:  Am J Hypertens       Date:  2011-03-10       Impact factor: 2.689

Review 8.  State-of-the-art treatment of hypertension: established and new drugs.

Authors:  Michel Burnier; Yann Vuignier; Gregoire Wuerzner
Journal:  Eur Heart J       Date:  2013-11-11       Impact factor: 29.983

9.  The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Authors:  Ian M Kronish; Amy I Lynch; Suzanne Oparil; Jeff Whittle; Barry R Davis; Lara M Simpson; Marie Krousel-Wood; William C Cushman; Tara I Chang; Paul Muntner
Journal:  Hypertension       Date:  2016-05-23       Impact factor: 10.190

10.  High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis.

Authors:  Maciej Tomaszewski; Christobelle White; Prashanth Patel; Nicholas Masca; Ravi Damani; Joanne Hepworth; Nilesh J Samani; Pankaj Gupta; Webster Madira; Adrian Stanley; Bryan Williams
Journal:  Heart       Date:  2014-04-02       Impact factor: 5.994

View more
  12 in total

1.  Chronotherapy as a potential approach to hypertensive patients with elevated heart rate?

Authors:  Fedor Simko; Tomas Baka
Journal:  Br J Clin Pharmacol       Date:  2019-06-20       Impact factor: 4.335

2.  Medication adherence-Key considerations for clinical pharmacologists.

Authors:  Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2020-02-25       Impact factor: 4.335

3.  Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence.

Authors:  Valeria Avataneo; Amedeo De Nicolò; Franco Rabbia; Elisa Perlo; Jacopo Burrello; Elena Berra; Marco Pappaccogli; Jessica Cusato; Antonio D'Avolio; Giovanni Di Perri; Franco Veglio
Journal:  Br J Clin Pharmacol       Date:  2018-08-15       Impact factor: 4.335

Review 4.  Resistant Hypertension Updated Guidelines.

Authors:  Irene Chernova; Namrata Krishnan
Journal:  Curr Cardiol Rep       Date:  2019-08-30       Impact factor: 2.931

5.  Identifying poor adherence to antihypertensive medications in patients with resistant hypertension.

Authors:  Isla S Mackenzie; Thomas M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

6.  Evidence of Nonadherence in Cases of Pseudoresistant Hypertension.

Authors:  João Marcos de Menezes Zanatta; Luciana Neves Cosenso-Martin; Valquíria da Silva Lopes; Jéssica Rodrigues Roma Uyemura; Aleandra Marton Polegati Santos; Manoel Ildefonso Paz Landim; Juan Carlos Yugar-Toledo; José Fernando Vilela-Martin
Journal:  Integr Blood Press Control       Date:  2021-02-11

7.  Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma.

Authors:  Amedeo De Nicolò; Alessandra Manca; Alice Ianniello; Alice Palermiti; Andrea Calcagno; Micol Ferrara; Miriam Antonucci; Jessica Cusato; Valeria Avataneo; Elisa De Vivo; Stefano Bonora; Francesco Giuseppe De Rosa; Giovanni Di Perri; Antonio D'Avolio
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13

Review 8.  Resistant hypertension-defining the scope of the problem.

Authors:  Richard Chia; Ambarish Pandey; Wanpen Vongpatanasin
Journal:  Prog Cardiovasc Dis       Date:  2019-12-19       Impact factor: 11.278

9.  A Six Sigma framework to successfully manage medication adherence.

Authors:  Bernard Vrijens
Journal:  Br J Clin Pharmacol       Date:  2019-03-04       Impact factor: 4.335

10.  A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease.

Authors:  Oscar Kristiansen; Nils T Vethe; Morten W Fagerland; Stein Bergan; John Munkhaugen; Einar Husebye
Journal:  Br J Clin Pharmacol       Date:  2019-11-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.